CY1118714T1 - Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2 - Google Patents

Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2

Info

Publication number
CY1118714T1
CY1118714T1 CY20171100144T CY171100144T CY1118714T1 CY 1118714 T1 CY1118714 T1 CY 1118714T1 CY 20171100144 T CY20171100144 T CY 20171100144T CY 171100144 T CY171100144 T CY 171100144T CY 1118714 T1 CY1118714 T1 CY 1118714T1
Authority
CY
Cyprus
Prior art keywords
human
catalogs
protection
high concentration
antibodies
Prior art date
Application number
CY20171100144T
Other languages
Greek (el)
English (en)
Inventor
Lynn Macdonald
Andrew J Murphy
Nicholas J Papadopoulos
Marc R Morra
Robert R Salzler
Michael L Lacroix-Fralish
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1118714T1 publication Critical patent/CY1118714T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20171100144T 2009-09-09 2017-02-01 Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2 CY1118714T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24078309P 2009-09-09 2009-09-09
US24282109P 2009-09-16 2009-09-16
US31783910P 2010-03-26 2010-03-26
PCT/US2010/048034 WO2011031695A1 (en) 2009-09-09 2010-09-08 High affinity human antibodies to human protease-activated receptor-2

Publications (1)

Publication Number Publication Date
CY1118714T1 true CY1118714T1 (el) 2017-07-12

Family

ID=43063654

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100144T CY1118714T1 (el) 2009-09-09 2017-02-01 Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2

Country Status (29)

Country Link
US (3) US8101724B2 (cg-RX-API-DMAC10.html)
EP (1) EP2475684B1 (cg-RX-API-DMAC10.html)
JP (2) JP5832435B2 (cg-RX-API-DMAC10.html)
KR (1) KR101766701B1 (cg-RX-API-DMAC10.html)
CN (1) CN102574923B (cg-RX-API-DMAC10.html)
AR (1) AR078346A1 (cg-RX-API-DMAC10.html)
AU (1) AU2010292342C1 (cg-RX-API-DMAC10.html)
BR (1) BR112012005338A2 (cg-RX-API-DMAC10.html)
CA (1) CA2773541A1 (cg-RX-API-DMAC10.html)
CY (1) CY1118714T1 (cg-RX-API-DMAC10.html)
DK (1) DK2475684T3 (cg-RX-API-DMAC10.html)
ES (1) ES2609780T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20170324T1 (cg-RX-API-DMAC10.html)
HU (1) HUE031725T2 (cg-RX-API-DMAC10.html)
IL (1) IL218501A (cg-RX-API-DMAC10.html)
JO (1) JO3246B1 (cg-RX-API-DMAC10.html)
LT (1) LT2475684T (cg-RX-API-DMAC10.html)
MX (1) MX2012002927A (cg-RX-API-DMAC10.html)
MY (1) MY159551A (cg-RX-API-DMAC10.html)
NZ (1) NZ599204A (cg-RX-API-DMAC10.html)
PL (1) PL2475684T3 (cg-RX-API-DMAC10.html)
PT (1) PT2475684T (cg-RX-API-DMAC10.html)
SG (1) SG178976A1 (cg-RX-API-DMAC10.html)
SI (1) SI2475684T1 (cg-RX-API-DMAC10.html)
SM (2) SMT201700102T1 (cg-RX-API-DMAC10.html)
TW (1) TWI492757B (cg-RX-API-DMAC10.html)
UY (1) UY32883A (cg-RX-API-DMAC10.html)
WO (1) WO2011031695A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201201730B (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
AP2014007588A0 (en) * 2011-09-22 2014-04-30 Amgen Inc CD27L antigen binding proteins
HK1223096A1 (zh) 2013-09-25 2017-07-21 Vertex Pharmaceuticals Incorporated 用作par-2信號通路抑制劑的咪唑並噠嗪
WO2015128846A1 (en) * 2014-02-28 2015-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
WO2017023780A1 (en) 2015-07-31 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting cd56-positive tumors
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
ES2984663T3 (es) 2015-11-13 2024-10-30 Oasis Pharmaceuticals Llc Moduladores del receptor 2 activados por proteasa
JP2019534044A (ja) 2016-11-08 2019-11-28 クイル ピュージェット サウンド バイオセラピューティクス コーポレーション 抗ｐｄ１および抗ｃｔｌａ４抗体
MA49886A (fr) 2017-03-16 2020-06-24 Medimmune Ltd Anticorps anti-par2 et leurs utilisations
US12077592B2 (en) * 2019-01-18 2024-09-03 Janssen Biotech, Inc. GPRC5D chimeric antigen receptors and cells expressing the same
AU2020250933A1 (en) 2019-04-05 2021-10-28 Centre Hospitalier Régional Et Universitaire De Brest Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
BR112021023897A2 (pt) 2019-05-30 2022-01-25 Shandong Boan Biotechnology Co Ltd Anticorpo ou receptor de antígeno quimérico que visa claudina18.2
WO2021084760A1 (ja) * 2019-11-01 2021-05-06 株式会社 資生堂 皮膚での活性型ｐａｒ－２を指標とした皮膚状態評価方法、ｐａｒ－２活性化促進剤又は抑制剤のスクリーニング方法及びｐａｒ－２活性化抑制剤
CN113248611B (zh) * 2020-02-13 2026-02-06 上海泰槿生物技术有限公司 抗bcma抗体、其药物组合物及应用
EP4126248A4 (en) 2020-03-31 2024-07-10 Fred Hutchinson Cancer Center HUMAN ANTI-CD33 ANTIBODIES AND THEIR USES
AU2021328375A1 (en) * 2020-08-18 2023-04-13 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
JP2024535740A (ja) * 2021-09-02 2024-10-02 メモリアル スローン ケタリング キャンサー センター Ｃｄ３３を標的とする抗原認識受容体及びその使用
EP4396235A4 (en) * 2021-09-02 2025-07-02 Memorial Sloan Kettering Cancer Center ANTI-CD33 ANTIBODIES AND THEIR USES
CN114181311B (zh) * 2021-12-20 2023-06-20 华东师范大学 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用
GB202204159D0 (en) * 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
WO2024059336A1 (en) * 2022-09-18 2024-03-21 Memorial Sloan Kettering Cancer Center Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema
CN118290572B (zh) * 2023-09-19 2026-04-07 军事科学院军事医学研究院军事兽医研究所 抗狂犬病病毒全人源抗体及其组合物与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297026B1 (en) 1993-07-26 2001-10-02 Cor Therapeutics Inc. Nucleic acids encoding the C140 receptor
EP1972194A1 (en) * 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US7888482B2 (en) * 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
WO2008086069A1 (en) * 2007-01-03 2008-07-17 The General Hospital Corporation Methods of treating itch
CL2008001887A1 (es) * 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
KR20090082619A (ko) 2008-01-28 2009-07-31 주식회사 알파크립텍 다프네틴을 함유하는 가려움증 또는 염증 개선용 화장료조성물
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
WO2010017086A1 (en) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Effectors of par-2 activation and their use in the modulation of inflammation
CN102458356A (zh) 2009-06-18 2012-05-16 株式会社爱茉莉太平洋 含有栗子皮提取物的化妆料组合物
WO2010147440A2 (ko) 2009-06-18 2010-12-23 (주)아모레퍼시픽 밤껍질 추출물을 포함하는 건강 식품 또는 약학 조성물
FR2947452B1 (fr) 2009-07-01 2012-04-20 Fabre Pierre Dermo Cosmetique L-serine et/ou l-asparagine et/ou l-valine pour prevenir et/ou au traiter des reactions inflammatoires de la peau.
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري

Also Published As

Publication number Publication date
HK1166509A1 (en) 2012-11-02
US20110059095A1 (en) 2011-03-10
MX2012002927A (es) 2012-08-03
IL218501A0 (en) 2012-07-31
JP5832435B2 (ja) 2015-12-16
PL2475684T3 (pl) 2017-04-28
US8425907B2 (en) 2013-04-23
SG178976A1 (en) 2012-04-27
JP6055055B2 (ja) 2016-12-27
CN102574923A (zh) 2012-07-11
KR20120059611A (ko) 2012-06-08
TW201121565A (en) 2011-07-01
MY159551A (en) 2017-01-13
SMT201700102T1 (it) 2017-03-08
IL218501A (en) 2017-03-30
DK2475684T3 (en) 2017-03-06
SMT201700102B (it) 2017-03-08
ES2609780T3 (es) 2017-04-24
US20120093824A1 (en) 2012-04-19
TWI492757B (zh) 2015-07-21
LT2475684T (lt) 2017-01-25
AU2010292342B2 (en) 2015-04-30
HRP20170324T1 (hr) 2017-04-21
NZ599204A (en) 2014-05-30
EP2475684B1 (en) 2016-11-30
PT2475684T (pt) 2017-02-10
WO2011031695A1 (en) 2011-03-17
CA2773541A1 (en) 2011-03-17
AU2010292342C1 (en) 2015-08-27
KR101766701B1 (ko) 2017-08-09
AU2010292342A1 (en) 2012-05-03
US9028819B2 (en) 2015-05-12
CN102574923B (zh) 2016-12-07
UY32883A (es) 2011-03-31
EP2475684A1 (en) 2012-07-18
SI2475684T1 (sl) 2017-03-31
ZA201201730B (en) 2012-11-28
US20140179903A1 (en) 2014-06-26
HUE031725T2 (en) 2017-08-28
JP2013504577A (ja) 2013-02-07
JP2015227381A (ja) 2015-12-17
JO3246B1 (ar) 2018-03-08
BR112012005338A2 (pt) 2016-11-22
AR078346A1 (es) 2011-11-02
US8101724B2 (en) 2012-01-24

Similar Documents

Publication Publication Date Title
CY1121097T1 (el) Ανθρωπινα αντισωματα κατα toy gfr 3 και μεθοδοι χρησης αυτων
CY1123404T1 (el) Αντι-girt αντισωματα
CY1124778T1 (el) Αντισωματα anti-asic1 και χρησεις αυτων
JOP20220225B1 (ar) ميوتينات إنترليوكين-21 وطرق العلاج
CY1117695T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα της ανθρωπινης αγγειοποιητινης-2
SG178976A1 (en) High affinity human antibodies to human protease-activated receptor-2
CY1123256T1 (el) Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
CY1123010T1 (el) Διεγερση γονιδιου τrail με μικρο μοριο απο κανονικα και ογκου κυτταρα ως αντικαρκινικη θεραπεια
CY1122060T1 (el) Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων
CY1122155T1 (el) Συζευγμενες ενωσεις που περιλαμβανουν αντισωματα τροποποιημενης κυστεϊνης
CY1118549T1 (el) Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CY1119960T1 (el) Μεθοδοι για την αυξηση της αποτελεσματικοτητας της folr1 θεραπειας του καρκινου
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
CY1114271T1 (el) Αντισωματα εξουδετερωσης, ανθρωπινου κυτταρομεγαλοϊου και χρηση αυτων
CY1119213T1 (el) Πρωτεϊνη p75ntr συνδεσης νευροτροφινης για θεραπευτικη χρηση
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
CY1118702T1 (el) Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
CY1116288T1 (el) Tnfsf απλης αλυσου μορια
CY1118668T1 (el) Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων
EA201590622A1 (ru) Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
CY1117331T1 (el) Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων
ECSP13012402A (es) Inmunoglobulinas con dominio variable dual y su uso